ReviewThe Journal of antimicrobial chemotherapy2026
Oxazolidinones in the Clinical Management of Staphylococcal Infection-Linezolid or Tedizolid? A review on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS).
Review in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
There is limited information in the existing literature regarding the choice of oxazolidinone in clinical practice to treat infections caused by staphylococcal species. As members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS) we have collaborated and written this narrative review aimed at clinicians considering these agents in practice. The review focuses on two medications, linezolid and tedizolid, with a comprehensive description of pharmacology aspects, adverse effects, drug interactions and contraindications, and we investigate the potential for treatment optimization. We anticipate that this article will provide support for those considering utilization of linezolid and tedizolid in clinical practice to treat staphylococcal species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.